This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bertrand, M. E. Articles by Rasch, W. Search for Related Content PubMed PubMed Citation Articles by Bertrand, M. E. Articles by Rasch, W.

(Circulation. 2000;101:131.)
© 2000 American Heart Association, Inc.

Clinical Investigation and Reports

Influence of a Nonionic, Iso-Osmolar Contrast Medium (Iodixanol) Versus an Ionic, Low-Osmolar Contrast Medium (Ioxaglate) on Major Adverse Cardiac Events in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty

A Multicenter, Randomized, Double-Blind Study

Michel E. Bertrand, MD; Enrique Esplugas, MD; Jan Piessens, MD; Wenche Rasch, PhD; for the Visipaque in Percutaneous Transluminal Coronary Angioplasty [VIP] Trial Investigators

From the Division of Cardiology, Lille University Heart Institute, Lille, France (M.E.B.); Hospital de Bellvitge Princeps D’Espanya, Barcelona (E.E.); Nycomed Amersham, Oslo, Norway; and Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium (J.P.).

Correspondence to M.E. Bertrand, MD, Division of Cardiology, Lille University Heart Institute, Boulevard du Professeur Leclercq, Lille, France. E-mail mbertrand{at}univ-lille2.fr

Background—The potential merits and disadvantages of the use of ionic or nonionic contrast media in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) have been the subjects of controversy. The present study was designed to evaluate the possible influence of both types of contrast media on major adverse cardiac events (MACE) in patients undergoing PTCA.

Methods and Results—In a randomized, parallel-group, double-blind study, 1411 patients received either iodixanol (a nonionic, iso-osmolar contrast medium) or ioxaglate (an ionic, low-osmolar contrast medium) during PTCA. A standardized anticoagulation regimen was followed. Patients were monitored in the hospital for 2 days and followed-up at 1 month. The primary end point, a composite of MACE (death, stroke, myocardial infarction, coronary artery bypass grafting, and re-PTCA) after 2 days, occurred in 4.3% of the total population, with no statistically significant difference between groups (iodixanol, 4.7%; ioxaglate, 3.9%; P=0.45). Further, between 2-day and 1-month follow-ups, no significant difference (P=0.27) existed between the groups in the rates of MACE. Hypersensitivity reactions (P=0.007) and adverse drug reactions (P=0.002) were significantly less frequent in the iodixanol group. The only significant predicting factors for the occurrence of MACE were dissection/abrupt closure and country.

Conclusions—No significant differences were observed between the iodixanol and ioxaglate groups with regard to MACE, although hypersensitivity and adverse drug reactions were significantly less frequent in patients who received iodixanol.

Key Words: contrast media • angioplasty • angiography • stents

This article has been cited by other articles:

				S.-H. Jo, T.-J. Youn, B.-K. Koo, J.-S. Park, H.-J. Kang, Y.-S. Cho, W.-Y. Chung, G.-W. Joo, I.-H. Chae, D.-J. Choi, et al. Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Patients With Renal Insufficiency Undergoing Coronary Angiography: The RECOVER Study: A Randomized Controlled Trial J. Am. Coll. Cardiol., September 5, 2006; 48(5): 924 - 930. [Abstract] [Full Text] [PDF]

				P. A. McCullough, M. E. Bertrand, J. A. Brinker, and F. Stacul A Meta-Analysis of the Renal Safety of Isosmolar Iodixanol Compared With Low-Osmolar Contrast Media J. Am. Coll. Cardiol., August 15, 2006; 48(4): 692 - 699. [Abstract] [Full Text] [PDF]

				J. A. Brinker, C. J. Davidson, and W. Laskey Preventing in-hospital cardiac and renal complications in high-risk PCI patients Eur. Heart J. Suppl., August 1, 2005; 7(suppl_G): G13 - G24. [Abstract] [Full Text] [PDF]

				M. Bertrand Contrast media--a contradiction? Eur. Heart J., January 2, 2002; 23(2): 172 - 173. [Full Text] [PDF]

				B. Scheller A reply Eur. Heart J., January 2, 2002; 23(2): 173 - 175. [Full Text] [PDF]

				B. Scheller A reply Eur. Heart J., November 1, 2001; 22(21): 2029 - 2031. [PDF]

				V. Legrand Ionic or non-ionic contrast during coronary intervention: does it make a difference? Eur. Heart J., March 1, 2001; 22(5): 353 - 354. [PDF]

				B Scheller, B Hennen, A Pohl, H Schieffer, and T Markwirth Acute and subacute stent occlusion; risk-reduction by ionic contrast media Eur. Heart J., March 1, 2001; 22(5): 385 - 391. [Abstract] [PDF]

				C. J. Davidson, W. K. Laskey, J. B. Hermiller, J. K. Harrison, W. Matthai Jr, R. E. Vlietstra, J. A. Brinker, D. J. Kereiakes, J. B. Muhlestein, A. Lansky, et al. Randomized Trial of Contrast Media Utilization in High-Risk PTCA : The COURT Trial Circulation, May 9, 2000; 101(18): 2172 - 2177. [Abstract] [Full Text] [PDF]